The potential Covid-19 vaccine is being developed by J&J subsidiary, Janssen Pharmaceutical, which will be responsible for the supply. Credit: pearson0612 from Pixabay.

The European Commission (EC) has approved an advance purchase agreement for (J&J) to supply 200 million doses of Covid-19 vaccine candidate to the European Union (EU) Member States, after approval or authorisation.

The EU also secured an option to procure an additional of up to 200 million doses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The potential Covid-19 vaccine is being developed by J&J subsidiary, Janssen Pharmaceutical, which will be responsible for the supply.

This agreement comes after the parties concluded exploratory discussions in August. J&J is currently in talks with additional stakeholders, including governments and global organisations, to enable worldwide access to its vaccine candidate against Covid-19.

Johnson & Johnson chief scientific officer and executive committee vice-chairman Paul Stoffels said: 鈥淭he Covid-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access to our Covid-19 vaccine as soon as we can.

鈥淲e appreciate the Commission鈥檚 and the Member States鈥� support for our Covid-19 vaccine candidate and development efforts.鈥�

Alongside this agreement with the EC, J&J plans to allocate up to 500 million doses of the vaccine toward global efforts focused on access for lower-income countries.

Following approval or authorisation from regulators, the delivery should begin mid next year.

In a separate development, Rentschler Biopharma agreed to serve as a contract development and manufacturing organisation (CDMO) partner for BioNTech, with focus on Covid-19 vaccine manufacturing support.

Initially, Rentschler will carry out current good manufacturing practice (cGMP) drug substance production of Covid-19 vaccine candidate, BNT162b2, developed by BioNTech in alliance with .

BNT162b2 is an mRNA-based vaccine currently in a Phase III trial at multiple sites globally.

According to the deal, Rentschler will perform downstream processing to deliver a purified drug substance by separating process and product-related impurities from the intermediate pool obtained previously from mRNA synthesis.

This is supposedly vital for the safety and tolerability of a vaccine for use in humans, and also to maximise the amount of mRNA collected from the initial production process.

Production of purified drug substance will take place at Rentschler鈥檚 headquarters in Laupheim, Germany.